The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177 Lu-Prostate-Specific Membrane Antigen Therapy
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.265759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Shejil Kumar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Royal North Shore Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Hypocalcemia, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
177Lu-prostate-specific membrane antigen (PSMA) is an effective treatment for metastatic castration-resistant prostate cancer. Rarer treatment-related adverse events have not yet been described.
Methods
We present case reviews of 2 men with a marked hypocalcemic osteosclerotic response to 177Lu-PSMA-I&T therapy. A clinical dataset of 177Lu-PSMA-I&T therapy was evaluated to estimate the incidence and clinical association with hypocalcemia.
Results
Forty-one of the 127 men (32%) had a serum calcium drop, and 6 (5%) developed clinical hypocalcemia during 177Lu-PSMA therapy. The baseline total tumor volume was significantly higher in those who developed hypocalcemia (median, 3,249 cm3 [interquartile range, 1,856-3,852] vs. 465 [interquartile range 135-1,172]; P = 0.002). The mean prostate-specific antigen response in those with hypocalcemia was 78% (SD, 24%).
Conclusion
Hypocalcemia may occur in response to 177Lu-PSMA-I&T, particularly with both high-volume bone metastases and a significant prostate-specific antigen response, and may be severe, requiring corticosteroids. Further evaluation of 177Lu-PSMA-induced hypocalcemia is required to better understand mechanisms, optimal treatments, and repercussions from any subsequent osteosclerotic response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
- St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
- Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
- Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
- School of Medical Science, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Zitieren
APA
Kumar, S., Crumbaker, M., Harvey, C., Pathmanandavel, S., John, N., Swiha, M. M., McDonald, M. M., Clifton-Bligh, R., Lee, A., Bastick, P., Counter, W., Nguyen, A., & Emmett, L. (2023). The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177 Lu-Prostate-Specific Membrane Antigen Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265759
Vancouver
Kumar S, Crumbaker M, Harvey C, Pathmanandavel S, John N, Swiha MM, et al. The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177 Lu-Prostate-Specific Membrane Antigen Therapy. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265759
BibTeX
@article{Kumar2023,
author = {Kumar, Shejil and Crumbaker, Megan and Harvey, Christopher and Pathmanandavel, Sarennya and John, Nikieth and Swiha, Mina M and McDonald, Michelle M and Clifton-Bligh, Roderick and Lee, Adrian and Bastick, Patricia and Counter, William and Nguyen, Andrew and Emmett, Louise},
title = {The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177 Lu-Prostate-Specific Membrane Antigen Therapy},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.265759}
}
EUVIMED